/
Oncology
Chronic Lymphocytic Leukaemia
14
Pipeline Programs↗
3
Active Trials↗
11
Companies Involved↗
Chronic Lymphocytic Leukaemia is an emerging landscape with 14 programs across 11 companies. The most active players are AstraZeneca.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical7
Phase 1
No programs
Phase 27
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
75%
Small molecule
9 of 12 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 12 classified programs, each share of the total. Modality classified for 93% of 14 pipeline programs.
Analysis
Trial Status
9
clinical trials
Completed3 · 33%
Unknown status2 · 22%
Recruiting2 · 22%
Withdrawn1 · 11%
Not yet recruiting1 · 11%
Clinical Trials
Trial Activity
9 trials
Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukaemia
Unknown status·—·N/A·NCT05145101·150 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)